For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Takeda Accelerating Tie-ups in CNS Field
April 18, 2011
- Pharmacists to Participate in Dispensing Bill Review Starting in June
April 18, 2011
- Domestic Generics-only Makers to Maintain Lead in GE Drug Market: Report
April 18, 2011
- DSP, BBI Enter Strategic Partnership on Anticancer Drugs
April 18, 2011
- Regulatory Reform Shelves Online Sale of OTC Drugs, Unification of Basic Dispensing Fees
April 18, 2011
- Nippon Chemiphar Introduces MR Team System on a Full Scale
April 18, 2011
- Eisai Reorganizes Its Businesses in East Asia
April 18, 2011
- Korosho Draws Up New GL for Clinical Evaluation of Drugs for Heart Failure
April 18, 2011
- Sawai's Cetirizine OD Tab Receives Generic Drug of Year Award
April 18, 2011
- Aftershocks Disrupt Production at Some Pharma Production Facilities
April 18, 2011
- Korosho to Introduce “Yellow Letter”for Patients
April 18, 2011
- Relaxation of Restrictions on Online Sale of OTC Drugs May Enter Agenda in May: President Kodama of JPA
April 18, 2011
- Gov't to Enforce 25% Power Cuts This Summer for Major Users Including Drug Makers
April 18, 2011
- Gov't Appeals to High Court in Iressa Case
April 18, 2011
- Taisho Acquires Hoepharma of Malaysia
April 18, 2011
- Korosho Calls on Industry to Come Up with Energy Conservation Plans
April 18, 2011
- FDA Approves 1st New Treatment for Late-stage Melanoma in Over a Decade: BMS
April 18, 2011
- Eiken Licenses LAMP Technology to OptiGene
April 18, 2011
- ASKA Begins Shipments of Thyradin Substitute
April 18, 2011
- Review Period for QAB149 for COPD Extended 3 Months by FDA
April 18, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…